BioCentury | Feb 16, 2018
Clinical News

Alopexx reports Phase I data for bacterial infection prevention candidate

...led to “robust bactericidal killing” of Neisseria gonorrhea and N. meningitidis , as well as opsonic...
BioCentury | Nov 29, 2017
Preclinical News

Researchers identify second macrophage inhibitory pathway as target for cancer immunotherapy

In a study published in Nature Immunology , researchers at Stanford University and colleagues found blocking major histocompatibility complex class I (MHCI) or leukocyte immunoglobulin-like receptor B1 (LILRB1) promoted phagocytosis of tumor cells, suggesting the pathway...
BioCentury | Nov 21, 2017
Preclinical News

Researchers develop mAb that enhances phagocytosis of tumor cells

In a paper published in Proceedings of the National Academy of Sciences , researchers at Stanford University and colleagues describe a mAb against signal regulatory protein alpha (SIRPA; CD172a; SHPS-1) that augments tumor killing when paired...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Pneumococcus Rabbit studies suggest a vaccine based on an S. pneumoniae CPS mimic could help prevent invasive pneumococcal disease caused by the pathogen's serotype 5. The vaccine consisted of a synthetic oligosaccharide mimic of...
BioCentury | Oct 13, 2017
Product Development

Eyeing complement data

Clinical studies of four complement inhibitors in patients with age-related macular degeneration suggest the best target in the pathway may be complement 3 . However, differences between study populations and methods and durations of treatment also...
BioCentury | Mar 25, 2017
Finance

Beyond Prevnar

Frazier Healthcare Partners had been tracking SutroVax Inc. 's progress since it spun out of Sutro Biopharma Inc. in 2013 and came on board to co-lead the company's $60 million series B round after preclinical...
BioCentury | Feb 22, 2016
Regulation

Extrapolating mAbs

FDA's Arthritis Advisory Committee's discussion and vote to recommend approval of the first biosimilar mAb shows that the mechanism of action of the reference product matters, and companies with biosimilars of mAbs approved for multiple...
BioCentury | May 28, 2015
Product R&D

Altermune's Alphamers

Altermune Technologies LLC is taking immunotherapy back to its day job of fighting infections with a new technology that coats bacteria with a sugar, and recruits circulating antibodies against the sugar to find and destroy...
BioCentury | Sep 18, 2014
Tools & Techniques

Bad blood

Whereas pharmacological approaches to treating sepsis have languished in the clinic, a mechanical approach has been designed by a Massachusetts team that cleanses pathogens and endotoxins from blood. 1 The microfluidic device could be a...
BioCentury | Oct 10, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Protease-resistant cytotoxic antibodies Engineered, protease-resistant, cytotoxic, therapeutic antibodies could have better efficacy than nonresistant counterparts. In protease incubation assays, combined mutations in the CH2 and...
Items per page:
1 - 10 of 17
BioCentury | Feb 16, 2018
Clinical News

Alopexx reports Phase I data for bacterial infection prevention candidate

...led to “robust bactericidal killing” of Neisseria gonorrhea and N. meningitidis , as well as opsonic...
BioCentury | Nov 29, 2017
Preclinical News

Researchers identify second macrophage inhibitory pathway as target for cancer immunotherapy

In a study published in Nature Immunology , researchers at Stanford University and colleagues found blocking major histocompatibility complex class I (MHCI) or leukocyte immunoglobulin-like receptor B1 (LILRB1) promoted phagocytosis of tumor cells, suggesting the pathway...
BioCentury | Nov 21, 2017
Preclinical News

Researchers develop mAb that enhances phagocytosis of tumor cells

In a paper published in Proceedings of the National Academy of Sciences , researchers at Stanford University and colleagues describe a mAb against signal regulatory protein alpha (SIRPA; CD172a; SHPS-1) that augments tumor killing when paired...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Pneumococcus Rabbit studies suggest a vaccine based on an S. pneumoniae CPS mimic could help prevent invasive pneumococcal disease caused by the pathogen's serotype 5. The vaccine consisted of a synthetic oligosaccharide mimic of...
BioCentury | Oct 13, 2017
Product Development

Eyeing complement data

Clinical studies of four complement inhibitors in patients with age-related macular degeneration suggest the best target in the pathway may be complement 3 . However, differences between study populations and methods and durations of treatment also...
BioCentury | Mar 25, 2017
Finance

Beyond Prevnar

Frazier Healthcare Partners had been tracking SutroVax Inc. 's progress since it spun out of Sutro Biopharma Inc. in 2013 and came on board to co-lead the company's $60 million series B round after preclinical...
BioCentury | Feb 22, 2016
Regulation

Extrapolating mAbs

FDA's Arthritis Advisory Committee's discussion and vote to recommend approval of the first biosimilar mAb shows that the mechanism of action of the reference product matters, and companies with biosimilars of mAbs approved for multiple...
BioCentury | May 28, 2015
Product R&D

Altermune's Alphamers

Altermune Technologies LLC is taking immunotherapy back to its day job of fighting infections with a new technology that coats bacteria with a sugar, and recruits circulating antibodies against the sugar to find and destroy...
BioCentury | Sep 18, 2014
Tools & Techniques

Bad blood

Whereas pharmacological approaches to treating sepsis have languished in the clinic, a mechanical approach has been designed by a Massachusetts team that cleanses pathogens and endotoxins from blood. 1 The microfluidic device could be a...
BioCentury | Oct 10, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Protease-resistant cytotoxic antibodies Engineered, protease-resistant, cytotoxic, therapeutic antibodies could have better efficacy than nonresistant counterparts. In protease incubation assays, combined mutations in the CH2 and...
Items per page:
1 - 10 of 17